ABBV
ABBVIE INC.
stockNYSE
At CloseNov 5, 2026 3:59:55 PM EST
288.24USD-2.235%(-6.59)7,881,434
Pre-marketNov 5, 2026 9:25:30 AM EST
298.88USD+1.374%(+4.05)
After-hoursNov 5, 2026 4:59:30 PM EST
288.25USD+0.003%(+0.01)
Loading…
Loading…
509.97B
Healthcare
Drug Manufacturers-General
CEO
Richard Gonzalez
HQ
North Chicago, IL, USA
30,000
Previous Close
$294.83
Beta
-0.10
52-Week High
$298.74 2026-10-30
52-Week Low
$190.75 2026-04-29
SMA 50
$270.78
SMA 200
$238.22
Avg. Vol 10D
5.56M
Avg. Vol 30D
5.23M
Avg. Vol 90D
5.17M
Relative Vol
0.70
1.77B
1.76B
99.82%
15,582,821
0.88%
2.72
53%/47%
19.67%
0.2500%
7,700,000
355
12,585
99,862
Apr 15, 2025 · $1.640
66.0B
10.3B
18.9B
32.16
-286.28
Nov 5, 2026
3 Dividend Kings to Buy in November and Never Sell · 
The Motley Fool
2 Growth Stocks to Buy in November Without Any Hesitation · The Motley Fool
ABBV Profile
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
ABBV Performance
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 290.79 | 2026-10-29 | -0.76% | 0.551 |
| 1M | 265.76 | 2026-10-05 | +8.59% | -0.106 |
| 3M | 246.20 | 2026-08-05 | +17.22% | -0.015 |
| 6M | 206.11 | 2026-05-05 | +40.02% | -0.473 |
| 1Y | 216.77 | 2025-11-05 | +33.13% | -0.099 |
| 2Y | 201.68 | 2024-11-05 | +43.09% | — |
| 5Y | 117.18 | 2021-11-05 | +146.28% | 0.283 |
ABBV Stock Summary
ABBVIE INC. (NYSE:ABBV) stock price today is $288.59, and today's volume is 3,648,832. ABBV is down 2.116% today. The 30 day average volume is 5.23M. ABBV market cap is $509.97B with 1.77B shares outstanding.